retatrutide mechanism triple agonist gip glp1 glucagon Frontiers The Road towards Triple Agonists:

A reduction in the liking subtype of reward eating was displayed in both men and women

Supporting Satiety and Maintaining Muscle Mass Encouraging the feeling of satiety to minimize the drive to overconsume calories is a central focus for GLP-1 therapy, and can be part of a protocol alongside GLP-1 drugs or encouraged through nutrition and supplementation alone

For comparison, in the table below, we also show those GLP-1 agonists with active ingredients only approved for treatment of diabetes that have less potential for off-label weight loss use (Bydureon BCise, Trulicity)

however, compounded drugs themselves are not FDA-approved